Huntington’s Disease 123 (HD123)

About

The primary goal of the study is to derive biomarkers that could be further developed to measure the efficacy of novel pharmacological treatments for HD.

Countries

United Kingdom

Number of participants

150 participants

Recruitment status

Not yet recruiting

Eligibility Criteria

Ages Eligible for Study: 21 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: Yes

Inclusion Criteria

Must be capable of giving informed consent
Must be willing to comply with adequate contraceptive measures
Must be considered by the Investigator to be in good heath (excluding disease under study

Exclusion Criteria

Individuals who do not meet inclusion criteria
Known intracranial comorbidities (i.e. stroke, haemorrhage, space-occupying lesions etc.)
The presence or history of other neurological or primary psychiatric disorders secondary to HD
Pregnancy
Breastfeeding
Contraindication to MRI (e.g. presence of metal devices, metal deposited in the body)